

12-28-1999



101231858

TUCKER FLYER
1615 L Street, N.W.
Washington, D.C. 20036
(202) 452-8600

D

MRD 12.16.99

<p>1. NAME OF CONVEYING PARTY:</p> <p>SOLVAY PHARMACEUTICALS B.V. Formerly SOLVAY DUPHAR B.V. A Netherlands corporation</p>	<p>2. NAME AND ADDRESS OF RECEIVING PARTY:</p> <p>GALDERMA S.A. a Swiss corporation Zugerstrasse 8 Cham, CH-6330, Switzerland</p>
<p>3. NATURE OF CONVEYANCE:</p> <p><input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input type="checkbox"/> Other</p> <p>3A. EXECUTION DATE: November 9, 1999 3B. EFFECTIVE DATE: October 6, 1996</p>	<p>2A. ASSIGNEE A FOREIGN ENTITY: Yes: <input checked="" type="checkbox"/> No: <input type="checkbox"/></p> <p>2B. DOMESTIC REPRESENTATIVE DESIGNATED: Yes: <input checked="" type="checkbox"/> No: <input type="checkbox"/></p> <p>Designation contained in Declaration of Excusable Non-Use (copy attached)</p>
<p>4A. TRADEMARK APPLICATION NOS.:</p> <p>Additional numbers attached?</p>	<p>4B. TRADEMARK REGISTRATION NO(S):</p> <p>Reg. No. 1,814,674 – SILKIS</p> <p>Additional numbers attached? NO</p>
<p>Henry W. Leeds, Esq. Tucker Flyer Suite 400 1615 L Street, N.W. Washington, D.C. 20036</p>	
<p>6. TOTAL NUMBER OF TITLES: 1</p> <p>7. TOTAL FEE: \$40.00 - Check Enclosed</p> <p>8. CHARGE ADDITIONAL FEES TO: DEPOSIT ACCOUNT NO. 20-1582</p> <p>Our Ref: 29500.329</p>	<p>9. The undersigned declares to the best of his knowledge and belief that the information on this cover sheet is true and correct and any copy submitted is a true copy of the original document.</p> <p><i>Henry W. Leeds</i> Henry W. Leeds Date: December 14, 1999</p> <p>Page 1 of 3</p> <div style="border: 1px solid black; border-radius: 50%; width: 80px; height: 80px; display: flex; align-items: center; justify-content: center; margin: 0 auto;"> <p style="writing-mode: vertical-rl; transform: rotate(180deg);">1014674</p> <p style="writing-mode: vertical-rl; transform: rotate(180deg);">40.00 DP</p> </div>

I hereby certify that the foregoing assignment was deposited with the U.S. Postal Services, by First Class Mail, postage prepaid, addressed to Box: Assignments Fee, The Assistant Commissioner of Trademarks, U.S. Patent and Trademark Office, 2900 Crystal Drive, Arlington, VA 22202-3513, this 14th day of December 1999.

Henry W. Leeds

029500-00329-00222.doc

TRADEMARK
REEL: 002003 FRAME: 0807

12/28/1999 TTON11 0000020 1014674 01 FC:481

NUNC PRO TUNC ASSIGNMENT

WHEREAS, Solvay Pharmaceuticals B.V. (formerly Solvay Duphar B.V.), a Netherlands corporation, having a principal business address at C.J. Van Houtenlaan 36, Weesp, Netherlands ("Assignor"), is the owner of the trademark SILKIS and the U.S. registration therefor, Reg. No. 1,814,674; and

WHEREAS, Galderma S.A., a Swiss corporation, having a principal address at Zugerstrasse 8, Cham, CH-6330, Switzerland ("Assignee"), acquired all rights, title and interest in and to the mark SILKIS, the goodwill of the business symbolized thereby, and the registration thereof from Assignor by a bill of sale dated October 6, 1996.

NOW, THEREFORE, good and valuable consideration being extant, Assignor has assigned and hereby assigns to Assignee, effective as of October 6, 1996, all of its rights, title and interest in and to the mark SILKIS, the goodwill of the business symbolized thereby and the registration thereof, Reg. No. 1,814,674.

Assignor further assigns to Assignee all right to sue for, to receive and to hold damages and profits accruing from past infringement of the mark SILKIS.

Assignor further warrants that there are no licenses, encumbrances or other agreements, either written, oral or implied, relating to the mark SILKIS of which Assignee is not aware, and that it believes it has good and valid title to the mark to assign to Assignee.


Assignor:

SOLVAY PHARMACEUTICALS B.V.

Date: 9 November, 1999

By: D.J.F.M. Broens

Title: Director of the Legal and
Trademarks Department



**DECLARATION OF EXCUSABLE NON-USE UNDER SECTION 8
OF THE TRADEMARK ACT OF JULY 5, 1946**

Mark: SILKIS
Reg. No.: 1,814,674
Dated: January 4, 1994
Class: 5

TO THE COMMISSIONER OF PATENTS AND TRADEMARKS:

HANS PETER FRICK and CLAUDE ROSSIER declare that:

1. They are members of the board of directors of Galderma S.A., a Swiss corporation, having a principal address at Zugerstrasse 8, Cham, CH-6330, Switzerland ("Galderma"), and are authorized to make this Declaration.
2. Galderma is the owner of U.S. Reg. No. 1,814,674 – SILKIS for "pharmaceutical preparations and substances for the treatment of dermatological disorders," pursuant to a bill of sale from Solvay Duphar B.V., a Netherlands corporation, dated October 6, 1996.
3. A *nunc pro tunc* assignment of U.S. Reg. No. 1,814,674 – SILKIS, effective October 6, 1996, is in the process of review and execution by Solvay Duphar B.V., and will be filed for recordation in the United States Patent and Trademark Office promptly after it is executed by Solvay Duphar, B.V. and received by Galderma.
4. Galderma has a *bona fide* intention to use the mark SILKIS in commerce in connection with a dermatological pharmaceutical preparation in the United States, but has been prohibited from selling and distributing the product in the ordinary course of trade until the product has been approved by the Federal Drug Administration ("FDA").
5. Since Galderma acquired U.S. Reg. No. 1,814,674, it has been conducting preliminary investigations preparatory to the filing of a new investigational drug application ("IND") with the FDA. Based on its present studies, Galderma believes that the IND application will be filed with the FDA in 2002 or early 2003.
6. After the IND application for the SILKIS product has been filed with the FDA, Galderma will commence using the SILKIS mark in commerce in the ordinary course of trade in the United States in connection with the product in its clinical trials.
7. As further evidence of Galderma's intention to use the SILKIS mark, it has already received approval from more than ten European countries for clinical trials of its SILKIS product in those countries.

8. The sole reason for the SILKIS mark not yet being used in connection with a dermatological pharmaceutical preparation in the ordinary course of trade in commerce in the United States is the government prohibition against selling the product until it has been approved by the FDA.

9. They declare that all statements made herein are of their own knowledge true and that all statements made on information and belief are believed to be true; and further that these statements were made with the warning that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of this Declaration or the registration in connection therewith.

POWER OF ATTORNEY


Galderma hereby appoints HENRY W. LEEDS and Norm D. St. Landau, each a member of the Bar of the District of Columbia, and each having an address c/o Tucker Flyer, P.C., 1615 L Street N.W., Suite 400, Washington, D.C. 20036-5612, to file this declaration with full power of substitution and revocation, to transact all business in the Patent and Trademark Office in connection therewith, and to represent the undersigned in all proceedings affecting the mark which may arise in the Patent and Trademark Office hereafter. **All powers of attorney heretofore granted are hereby revoked.**

Please direct all correspondence to **HENRY W. LEEDS**.


DESIGNATION OF DOMESTIC REPRESENTATIVE

HENRY W. LEEDS, having an address c/o Tucker Flyer, P.C., 1615 L Street N.W., Suite 400, Washington, D.C. 20036-5612, is hereby designated Applicant's domestic representative upon whom notices or process in proceedings affecting the above-referenced mark may be served.

GALDERMA S.A.

By: 

Hans Peter Frick

By: 

Claude Rossier

Dated: November 18, 1999